Goldman Sachs’s Artiva Biotherapeutics ARTV Stock Holding History
Bought
Maintained
Sold
Other funds holding ARTV
Goldman Sachs's ARTV Position: Q3 2026 in Review
Goldman Sachs increased its Artiva Biotherapeutics (ARTV) stake by 860% in Q3 2026, buying an estimated $1.37M and bringing the position to 151,457 shares worth $1.08M. The position accounts for ﹤0.01% of the portfolio, ranked #5176.
Goldman Sachs first reported a position in ARTV in Q3 2024 and has held it in 9 quarters since. 98 funds tracked by Wall St. Rank hold ARTV as of Q3 2026.
- Goldman Sachs held 151,457 shares of Artiva Biotherapeutics worth $1.08M as of Q3 2026.
- Goldman Sachs bought 135,677 Artiva Biotherapeutics shares in Q3 2026, an estimated $1.37M.
- Artiva Biotherapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q3 2026, its #5176 holding.
- Goldman Sachs first reported a position in Artiva Biotherapeutics in Q3 2024 and has held it in 9 quarters since.
- 98 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q3 2026.
Based on Goldman Sachs's 13F filing for Q3 2026, filed 16 Nov 2026.